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ABSTRACT
Transcription factor Foxm1 plays a critical role
during embryonic development and its expression
is repressed during retinoic acid (RA)-induced
differentiation of pluripotent P19 embryonal car-
cinoma cells at the early stage, correlated with
downregulation of expression of pluripotency
markers. To study whether Foxm1 participates in
the maintenance of pluripotency of stem cells, we
knock down Foxm1 expression in P19 cells and
identify that Oct4 are regulated directly by Foxm1.
Knockdown of Foxm1 also results in spontan-
eous differentiation of P19 cells to mesodermal
derivatives, such as muscle and adipose tissues.
Maintaining Foxm1 expression prevents the down-
regulation of pluripotency-related transcription
factors such as Oct4 and Nanog during P19 cell dif-
ferentiation. Furthermore, overexpression of FOXM1
alone in RA-differentiated P19 cells (4 days) or
human newborn fibroblasts restarts the expression
of pluripotent genes Oct4, Nanog and Sox2.
Together, our results suggest a critical involvement
of Foxm1 in maintenance of stem cell pluripotency.
INTRODUCTION
Pluripotent stem cells are undifferentiated cells that can
give rise to several lineages of differentiated cell types (1).
They are the founder cells for every organ, tissue and cell
in the body. These cells are characterized by the ability to
self-renew and maintain pluripotency, which allows them
to fulﬁll their multiple functions, namely to provide
enough cells during organogenesis, to control tissue
homeostasis and, in addition, to ensure regeneration and
repair. Among the well-established pluripotent cells, such
as embryonic stem cells (ESCs) and embryonic germ cells
(EGCs), embryonal carcinoma cells (ECCs) are derived
from teratocarcinomas and have been well characterized
as pluripotent cell lines that can be maintained as undif-
ferentiated cells and induced under controlled conditions
to differentiate in vitro to any cell type of all three germ
layers (2), providing an attractive cell model system for
studying pluripotent stem cells. The mouse P19 EC cell
line was derived from a teratocarcinoma in C3H/He
mice, produced by grafting an embryo at 7 days of gesta-
tion to testes of an adult male mouse (3). The cells contain
a normal karyotype, predicting that the cells do not
possess any gross genetic abnormalities. When injected
into mouse blastocysts, P19 cells differentiate into a
broad range of cell types in the resulting chimeras (4).
P19 cells can differentiate in vitro into derivatives of all
three germ layers depending on chemical treatment and
growth conditions (5–7).
Understanding how pluripotency is regulated will have
a large impact on developmental biology studies and re-
generative medicine. Several transcription factors are
required for maintenance of pluripotency, including Oct4
Sox2, and Nanog, and inactivation of these genes leads to
loss of pluripotent stem cells and aberrant differentiation
(8–11). Recently, overexpression of a cocktail of transcrip-
tion factors (Oct4, Sox2, c-Myc and Klf4 or Oct4, Sox2,
Lin-28 and Nanog) has resulted in the induction of
pluripotency in somatic cells (12–14). These induced pluri-
potent stem cells (iPSCs) have all the properties of pluri-
potent cells, and the mechanism of this induction includes
modiﬁcation of epigenetics that mediate large-scale regu-
lation of gene expression patterns (15). Growing evidence
suggests that additional factors also contribute to the
control of pluripotency (16,17) and identiﬁcation of
novel factors that are involved in maintenance of
pluripotency is crucial and necessary for future applica-
tion of pluripotent stem cell derivatives in regenerative
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Transcription factor Foxm1 belongs to the fork head/
winged-helix family of transcription factors that play im-
portant roles in maintaining pluripotency (18,19), cellular
proliferation and differentiation during embryonic devel-
opment (20–23) and also play roles in cancer (24). Foxm1
is expressed in proliferating mammalian cells (25,26),
where it regulates transcription of cell cycle genes critical
for progression into DNA replication and mitosis(27–30).
Foxm1 has been shown to be highly expressed in
multipotent progenitor cells, such as proliferating neural
stem cells in germinal regions of central nervous system
(31,32) and progenitor cells of hair follicles (33), and to
inhibit differentiation of the progenitors, implicating that
Foxm1 plays in maintaining multipotent progenitor cells
from divergent embryonic lineages. Although the func-
tions of Foxm1 in pluripotent cells are not characterized,
we have found in this study that pluripotent stem
cells express Foxm1 and its expression is dramatically
downregulated upon differentiation, suggesting that
Foxm1 expression in pluripotent stem cells is functionally
signiﬁcant. Thus, Foxm1 appears to be a likely candidate
for searching novel factors in controlling the pluripotency
of stem cells.
In this study, we have investigated the possible role of
Foxm1 in maintenance of pluripotency of P19 EC cells.
We have shown that in response to retinoic acid (RA)
treatment, P19 cells lose their pluripotency rapidly,
evidenced by decreased expression of pluripotent stem
cell markers, and Foxm1 expression is also repressed.
The downregulation of Foxm1 protein levels happens
before the decrease of Oct4 and Nanog upon differenti-
ation. We have used an adenovirus-based vector to
express Foxm1-speciﬁc siRNA to knock down Foxm1
expression in pluripotent P19 cells. The expression of
Oct4 and Nanog are diminished by Foxm1 knockdown
and the Oct4 promoter is regulated directly by Foxm1.
Knockdown of Foxm1 in P19 cells also results in spon-
taneous differentiation of P19 cells to mesodermal deriva-
tives, such as muscle and adipose tissues. We have used
an adenovirus vector to maintain Foxm1 expression,
which results in the prevention of Oct4 and Nanog
downregulation during P19 cell differentiation. In
differentiated cells, such as RA-differentiated P19 cells
(4 days) or human newborn ﬁbroblasts, overexpression
of FOXM1 alone restarts the expression of Oct4, Nanog
and Sox2. Together, our results suggest a critical in-
volvement of Foxm1 in maintenance of stem cell
pluripotency.
MATERIALS AND METHODS
Cell culture and RA-induced neural differentiation
The P19 EC cell line and human newborn ﬁbroblasts was
purchased from ATCC. Adenovirus-puriﬁcation 293A cell
line was purchased from Invitrogen. P19 cells were main-
tained in Dulbecco’s modiﬁed Eagle’s medium (DMEM)
containing 7.5% calf serum, 2.5% fetal bovine serum
(Gibco) and 0.5% penicillin streptomycin (Gibco) at
37 Ci n5 %C O 2. 293A and human newborn ﬁbroblasts
were maintained in DMEM containing 10% fetal bovine
serum. For RA-induced differentiation, P19 cell aggre-
gates were formed by placing 3 10
6 cells in a 100mm
bacteriological dish (Petri dish) (Falcon) with addition
of 5 10
 7M all-trans-RA (Sigma) for 4 days.
Subsequently, the aggregates were replated on tissue
culture dishes (Corning) for further differentiation.
Adenovirus puriﬁcation, infection and siRNA treatment
The adenovirus-based vector AdFoxm1siRNA that
expresses Foxm1-speciﬁc siRNA was constructed with
Invitrogen Block-it Adenoviral RNAi Expression System
(Cat. No K4941-00 and V492-20), following the manufac-
turer’s instructions. A siRNA sequence 50-GGA CCA
CTT CCC TTA CTT T-3 from mouse Foxm1 cDNA
was used to design a double-strand DNA that
was recombinated into the adenovirus vector. The con-
structions of human FOXM1-expression adenovirus
AdFOXM1 and control virus AdLacZ or AdGFP were
described previously (34). The large-scale adenovirus puri-
ﬁcation and viral infections were carried out as previously
described (35). For siRNA treatment, mOct4 siRNA
(sc-36124) and control siRNA (sc-37007) were purchased
from Santa Cruz. The siRNA transfection was performed
according to the manufacturer’s instructions.
Isolation of RNA, reverse transcription polymerase chain
reaction and quantitative real-time PCR
Total RNA isolated from cell cultures were routinely used
for reverse transcription polymerase chain reaction
(RT-PCR) or quantitative real-time PCR (qPCR). Total
RNA was prepared by using RNAprep Pure Cell/Bacteria
Kits (Tiangen Biotech, China), following the manufac-




Synthesis Kits (Fermentas) with total RNA as templates.
PCR ampliﬁcation was performed with Taq DNA poly-
merase (Promega) with following sense (S) and antisense
(AS) primers, annealing temperature (Ta) and number of
PCR cycles (N): mFoxm1-S, 50-CAC TTG GAT TGA
GGA CCA CTT-30 and mFoxm1-AS, 50-GTC GTT
TCT GCT GTG ATT CC-30 (Ta: 57.5 C N: 35);
mOct4-S, 50-CAC TTT GGC ACC CCA GGC TA-30
and mOct4-AS, 50-GCC TTG GCT CAC AGC ATC
CC-30 (Ta:5 8  C, N: 30); mSox2-S, 50-TGA CCA GCT
CGC AGA CCT AC-30 and mSox2-AS 50-GGA GGA
AGA GGT AAC CAC GG -30 (Ta:5 5  C, N: 35);
mFgf4-S, 50-CAC GCG GCA CGC AGA ATT GG-30
and mFgf4-AS, 50-ATG CTC ACC ACG CCT CGC
TG-30 (Ta:6 0  C, N: 30); mCripto-S, 50-CAT GGC ACC
TGG CTG CCC AA-30 and mCripto-AS, 50-GGC AGG
CGC CAG CTA GCA TA-30 (Ta:6 0  C, N: 30); mEras -S,
50-TGG GCG TCT TTG CTC TTG-30 and mEras -AS
50-TCG GGT CTT CTT GCT TGA TT-30 (Ta:6 2  C, N:
35); mUtf1-S, 50-CCG TCG CTA CAA GTT CCT CA-30
and mUtf1-AS, 50-GCA GCA ACG CGG TAT TCA-30
(Ta: 58.5 C, N: 30); mEsg1-S, 50-TGG TGA CCC TCG
TGA CCC GT-30 and mEsg1-AS, 50-ACA TGG CCT
GGC TCA CCT GC-30 (Ta:6 3  C, N: 30); mRex1-S,
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mRex1-AS, 50-GCG TGG GTT AGG ATG TGA AT-30
(Ta: 57.5 C, N: 30); mCyclophilin-S, 50-GGC AAA TGC
TGG ACC AAA CAC-30 and mCyclophilin-AS, 50-TTC
CTG GAC CCA AAA CGC TC-30 (Ta: 57.5 C, N: 22);
hFOXM1-S, 50-GGA GGA AAT GCC ACA CTT AGC
G-30 and hFOXM1-AS, 50-TAG GAC TTC TTG GGT
CTT GGG GTG-30 (Ta: 55.7 C, N: 35); hOct4-S, 50-AAG
CGA TCA AGC AGC GAC TAT-30 and hOct4-AS,
50-GGA AAG GGA CCG AGG AGTA CA-30 (Ta:
60 C, N: 30); hNanog-S, 50-CAA AGG CAA ACA
ACC CAC TT-30 and hNanog-AS, 50-TCT GCT GGA
GGC TGA GGT AT-30 (Ta:6 0  C, N: 30); hSox2-S,
50-ACC TAC AGC ATG TCC TAC TC-30 and
hSox2-AS, 50-CAT GCT GTT TCT TAC TCT CCT
C-30 (Ta:6 0  C, N: 32); and hCyclophilin-S, 50-GCA
GAC AAG GTC CCA AAG ACA G-30 and
hCyclophilin-AS, 50-CAC CCT GAC ACA TAA ACC
CTG G-30 (Ta: 55.7 C, N: 22). For qPCR, two samples
were collected at each time point. Each sample was
analyzed in triplicate with cyclophline as the inner
control by real-time PCR with SYBR Green Supermix
(Bio-Rad, USA). Ampliﬁcation data were collected by
Mastercycler ep realplex and analyzed by the realplex2.0
software (Eppendorf).
Western blot analysis and ﬂow cytometry
To measure protein levels, cell lysates were resolved by
denaturing gel electrophoresis before electrotransfer to
Protran nitrocellulose membrane. The membrane was sub-
jected to western blot analysis with antibodies against
proteins of interest as described previously (36). The
signals from the primary antibody were ampliﬁed by
horse radish peroxidase (HRP)-conjugated anti-mouse or
anti-rabbit IgG (Bio-Rad, Hercules, CA, USA), and
detected with Enhanced Chemiluminescence Plus (ECL-
plus, Amersham Pharmacia Biotech, Piscataway, NJ,
USA). The following antibodies and dilutions were used
for western blotting: rabbit anti-Foxm1 (1:500; abcam
ab47808), rabbit anti-Oct4 (1:500; Chemicon AB3209),
rabbit anti-Nanog (1:2500; Chemicon AB9220), rabbit
anti-Sox2 (1:1000; abcam ab59776), rabbit anti-Nestin
(1:2500; Chemicon AB5922), mouse anti-Tubulin
bIII (1:1000; Chemicon MAB1637) and mouse anti-
b-Actin (1:10000; Sigma AC-15). For ﬂow cytometry,
cells at the certain time point were dissociated with
0.025% trypsin and 10
7 cells were incubated with 10ml
of antibody against protein of interest in 100ml buffer
(0.5% BSA, 2mM EDTA, 1X PBS) for 10min at 4 C.
The cells were washed by adding 2ml buffer and
centrifuged 10min (300g) and resuspended in 500ml
buffer. Samples were analyzed for ﬂow cytometry on
FACSCalibur (BD Biosciences) with SSEA-1-PE
antibody (R&D Systems FAB2155P).
Teratoma formation
Cells (1.5 10
6 cells/mouse) were injected subcutaneously
into the dorsal ﬂank of 6-week-old male nude mice. Three
weeks after the injection, teratomas that had formed were
ﬁxed overnight in 4% PFA and embedded in parafﬁn.
Sections were stained with hematoxylin and eosin dyes.
Alkaline phosphatase staining
Cells were ﬁxed with 50% acetone and 50% methanol at
room temperature for 2min and stained using an alkaline
phosphatase (ALP) staining kit (Vector Laboratories
Burlingame) according to a standard protocol.
Chromatin immunoprecipitation assays and
cotransfection assays
Chromatin immunoprecipitation (ChIP) assays were per-
formed as previously described (35). For immunopre-
cipitation, 2ml of rabbit anti-FOXM1 serum (27) or
control serum was used. The ChIP DNA sample or 5%
total input was used in PCR reaction with the following
primers: mOct4 promoter  3155bp forward: 50-GCC
TTG GAC CTT TGT TCT TAT CAC-30 and mOct4
promoter  2985bp backward: 50-TCT GTC TCG GAG
TTC TGT CTG GAG-30 (Ta:5 6  C, N: 35); and mOct4
promoter  1335bp forward: 50-GGA GCA GAC AGA
CAA ACA CCA TC-30 and mOct4 promoter  1148bp
backward: 50-TGG CGG AAA GAC ACT AAG GAG
AC-30 (Ta: 62.5 C, N: 35).
For cotransfection assays, the mouse Oct4 promoter
regions were PCR ampliﬁed from mouse genomic DNA
with the following primers: mOct4  1331 Mlu1: 50-CGA
CGC GTC AGA GCA TGG TGT AGG AGC A-30 or
mOct4-1249 Mlu1: 50-CGA CGC GTT AAG CAC CAG
GCC AGT AAT G-30, and mOct4+29 BglII: 50-GGA
AGA TCT GTG GAA AGA CGG CTC ACC TA-30,
and cloned into the corresponding Mlu1 and BglII sites
of the pGL3 basic Luciferase vector (Promega). The
mouse Oct4 promoter  3550 to  2817 region was PCR
ampliﬁed from mouse genomic DNA with the following
primers: mOCT4  3550 Mlu1: 50-CGA CGC GTC TAA
CAC GAG TGA TTT CCC TGC TC-30 and mOct4-2817
Mlu1 backward: 50-CGA CGC GTG GTG TCT GAA
GTA CTT ACG-30, and cloned into the corresponding
Mlu1 site of pGL3-Oct4-1361-bp-promoter. The site-
directed mutagenesis was performed by GenScript. P19
cells were transfected with 200ng of either CMV-
FOXM1 cDNA or CMV empty expression vectors and
1500ng of the Luciferase reporter constructs containing
different mouse Oct4 promoter regions using Lipofecter
2000 (Invitrogen). Protein extracts were prepared from
transfected P19 cells at 48h following DNA transfection
and the Dual-Luciferase Assay System (Promega) was
used to measure Luciferase enzyme activity following the
manufacturer’s instructions.
Statistical analysis
We used Microsoft Excel Program to calculate SD and
statistically signiﬁcant differences between samples using
the Student’s t-test. The asterisks in each graph indicate
statistically signiﬁcant changes with P-values calculated by
Student’s t-test: *P<0.05, **P 0.01 and ***P 0.001.
P-values<0.05 were considered statistically signiﬁcant.
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To conﬁrm that P19 EC cells are pluripotent stem cells, we
tested whether the cells were capable of forming teratomas
upon subcutaneous inoculation into nude mice. The tera-
tomas formed by P19 cells contained tissues of all three
germ layers including neural rosette (ectoderm), cuboidal
epithelium (endoderm) and muscle (mesoderm)
(Supplementary Figure S1A), revealing that P19 cells
possess the pluripotency. P19 cells were known to differ-
entiate to neural cells by RA treatment in vitro when
aggregated to form embryoid bodies (EBs) (5,7). We con-
ﬁrmed that RA-induced P19 cell neural differentiation
displayed at least three phases: the ﬁrst phase in which
P19 cells lost their pluripotency, marked by decrease of
alkaline phosphatase activity (Supplementary Figure S1B)
and disappearance of the expression of the pluripotency
marker Nanog at RA induction (Supplementary
Figure S1C); the second phase in which certain percentage
of P19 cells committed to the neural differentiation and
neural stem-like cells appeared, evidenced by elevated ex-
pression of neural stem cell marker Nestin that peaked at
Day 3 after RA treatment (Supplementary Figure S1C)
and increased cell populations positive with neural stem
cell-surface marker Prominin-1 (homolog of human
CD133) (Supplementary Figure S1D); and the terminal
differentiation phase (6–7 days following RA treatment)
in which differentiated neuronal cell populations
appeared, evidenced by elevated expression of
neuron-speciﬁc marker NeuroD1 and Tubulin bIII
(Supplementary Figure S1C and S1E-K).
Foxm1 is repressed at early time points during
differentiation and knockdown of Foxm1
results in loss of pluripotency of P19 cells
Transcription factor Foxm1 highly expressed in P19 pluri-
potent cells and its expression decreased dramatically
between Day 1 to Day 2 following RA treatment
(Figure 1A and B), suggesting the reduction of Foxm1
was one of the early events during differentiation of the
pluripotent cells and Foxm1 might participate in the main-
tenance of P19 cell pluripotency. The reduction of Foxm1
expression post RA treatment was correlated with the
decreased expression of many of the known
pluripotency-related genes, such as Oct4, Nanog, Sox2,
Fgf4, Cripto and Utf1 (Figure 1A and B and
Supplementary Figure S2). Interestingly, the down-
regulation of Foxm1 occurred before the decrease of
Oct4 expression during differentiation, implicating
that Foxm1 might be one of the upstream controlling
factors of Oct4 expression in the maintenance of stem
cell pluripotency. This idea was further conﬁrmed
by Foxm1 knockdown experiments, in which the infection
of AdFoxm1siRNA resulted in the decreased activity
of alkaline phosphatase in P19 cells (Figure 1C). Control
adenovirus infections determined that almost 100% of
the cells were infected with the viral dosage at
10 plaque-forming units (pfu)/cell (35) and the infection
of AdFoxm1siRNA could knockdown the Foxm1
mRNA expression around 95% (Figure 1D, qPCR).
The decreased expression of Foxm1 resulted in
downregulation of levels of cell cycle-related genes such
as Cyclin D1, Skp2, Cdc25B and Cdk1 and consequently
the decrease of proliferation rate in P19 cells
(Supplementary Figure 3S) as expected because Foxm1
was found to stimulate transcription of cell cycle genes
critical for progression into DNA replication and mitosis
(27–30). On the other hand, knockdown of Foxm1 does
not affect survival of P19 cells (Supplementary Figure S3
and Figure 3C). The inhibition of Foxm1 expression by
AdFoxm1siRNA also abolished the expression of Oct4
and Nanog in P19 cells (Figure 1D and E), implicating
that the levels of Oct4 and Nanog in pluripotent stem
cells rely on the Foxm1 expression. Taken together, our
data reveal that Foxm1 highly expressed in the undiffer-
entiated P19 pluripotent cells and was downregulated
by the differentiation process. Importantly, inhibition of
its expression caused the loss of pluripotency of P19
cells, implying its role in maintaining the pluripotency of
stem cells.
Knockdown of Foxm1 resulted in spontaneous
mesodermal differentiation of P19 cells
To test whether knockdown of Foxm1 promoted spontan-
eous differentiation in P19 cells, we analyzed the expres-
sion levels of differentiation markers in AdFoxm1siRNA-
infected P19 cells, including Map2 (ectoderm), Brachyury
(mesoderm) and Gata4 (endoderm). Without obvious
effects on the expression of Map2 and Brachyury (data
not shown), knockdown of Foxm1 in P19 cells resulted
in a rapid increase of Gata4 expression (Figure 2A). Gata4
was known to be one of the major transcription factors
that stimulated cardiogenesis during development (37–39)
even though it was frequently used as a marker for endo-
dermal derivatives during differentiation of pluripotent
stem cells (40). Flow cytometry was performed to
measure the expression of SSEA-1, which highly expresses
in mouse pluripotent stem cells, in P19 cells and
AdFoxm1siRNA-infected P19 cells (3d). We used mouse
embryonic ﬁbroblasts as negative control cells and mouse
ES cells as positive control cells. AdFoxm1siRNA infec-
tion resulted in signiﬁcant decrease of SSEA-1 in P19 cells
(Figure 2B). We performed the teratoma formation
in vivo with AdFoxm1siRNA-infected P19 cells and
found that P19 cells with decreased levels of Foxm1
produced signiﬁcantly smaller teratomas (Figure 2C).
Compared with the control P19 cell-formed teratomas,
which expressed all three germ layer differentiation
markers, teratomas formed with AdFoxm1siRNA-
infected P19 cells only expressed mesodermal marker
Brachyury (Figure 2D). Moreover, the expression of
cardiac muscle-speciﬁc Actc1 was detected in
AdFoxm1siRNA-infected teratomas, implicating that in-
hibition of Foxm1 limited the multipotentials of P19 cell
differentiation and caused P19 cell spontaneous differen-
tiation to cardiomyocytes in vivo. This possibility was
further conﬁrmed by hematoxylin and eosin-stained
sections from teratomas of AdFoxm1siRNA-infected
P19 cells, in which only mesodermal derivatives such as
muscle and adipose connective tissues were observed
(Figure 2E).
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To test whether Foxm1 was one of the regulators of Oct4
transcription, we scanned  5kb promoter region of
mouse Oct4 gene with the Foxm1 DNA binding consensus
sequence, and found multiple tandem Foxm1 putative
binding sites at the regions of  3434 to  3415bp,
 2895 to  2880bp and  1328 to  1313bp in the Oct4
promoter (Figure 3A). We used ChIP assays to determine
the Oct4 promoter regions that mediate Foxm1 binding to
endogenous Oct4 promoter at physiological conditions.
The chromatin of P19 cells or RA-induced (3d) P19 cells
was cross-linked, sonicated to DNA fragments of 500–
1000nt in length, and then immunoprecipitated (IP) with
either rabbit Foxm1 antiserum or rabbit serum (control).
The amount of promoter DNA associated with the IP
chromatin was quantitated by RT-PCR with primers
speciﬁc to Oct4 promoter region  3155bp to  2985bp
or  1335bp to  1148bp. Compared to the RA treated
Figure 1. The expression of Foxm1 was repressed during RA-induced P19 cell differentiation and knockdown of Foxm1 decreased alkaline phos-
phatase activity and the expression of pluripotency genes. (A and B) Gene expression analysis of Foxm1, Oct4, Nanog and Sox2 during RA-induced
differentiation of P19 cells by RT-PCR or quantitative real-time PCR (qPCR) (A) or western blotting (B). Cyclophilin or b-actin was used as the
loading control. (C) P19 cells, P19 cells infected with AdGFP control virus or AdFoxm1siRNA virus (10pfu/cell, 3 days) were stained for alkaline
phosphatase. (D and E) Knockdown of Foxm1 decreased the expression of pluripotency markers in P19 cells. P19 cells were infected with AdGFP or
AdFoxm1siRNA (10pfu/cell) and gene expression analysis of Foxm1, Oct4, Nanog and Sox2 was performed by RT-PCR or qPCR (D) or western
blotting (E).
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pluripotent cell samples showed obvious binding activities
of Foxm1 on the Oct4 promoter region around  3kb but
not the  1.3kb region (Figure 3B). These results con-
ﬁrmed that Foxm1 bound directly to endogenous Oct4
promoter at  3kb upstream region in pluripotent stem
cells. To test whether Foxm1 activates Oct4 promoter,
luciferase reporter plasmids with different length of
mouse Oct4 promoter regions were constructed and trans-
fected into P19 cells with the CMV-Foxm1 expression
vector or a CMV empty expression vector. Luciferase
enzyme activity was analyzed following transfection.
Cotransfection of Foxm1 expression vector caused a
signiﬁcant increase in  3kb Oct4 promoter activity
(Figure 3C). The activities of Oct4 promoters with differ-
ent length were inhibited at different levels during
RA-induced P19 cell differentiation (Figure 3D).
Furthermore, only the activities of the Oct4 promoter
that binds Foxm1 were affected signiﬁcantly by Foxm1
depletion (Figure 3E). To further prove that Oct4 is a
bona ﬁde target for Foxm1, we generated point mutations
on the Foxm1 putative binding site A and B, and found
that the luciferase activities of mutated promoters were
decreased signiﬁcantly compared with that of the intact
promoter when cotransfected with the Foxm1 expression
plasmid (Figure 3F). Together, these results demonstrated
that the Oct4 gene was one of the direct transcriptional
targets of Foxm1 in pluripotent stem cells.
Maintained expression of FOXM1 prevented the
downregulation of pluripotency marker expression
during P19 cell differentiation
In order to determine the effects of maintained Foxm1
expression during differentiation of P19 cells, we used an
adenovirus vector AdFOXM1 (34) constructed with
human FOXM1 cDNA to prevent the downregulation
of Foxm1 protein post RA treatment. AdFOXM1 infec-
tion resulted in efﬁcient expression of exogenous human
FOXM1, with no effects on the expression of endogenous
Foxm1 in P19 cells (Figure 4A). Then, P19 cells infected
with AdFOXM1 were induced to differentiation accord-
ing to the standard protocol one day after viral infection.
Maintained expression of FOXM1 prevented the decrease
of mRNA levels of pluripotency genes such as Oct4,
Nanog, Sox2 and endogenous Foxm1 that were
downregulated by differentiation in P19 cells or control
AdGFP-infected P19 cells (Figure 4B). The analysis of
Oct4 protein levels conﬁrmed the prevention of Oct4
protein decrease during P19 cell differentiation by
AdFOXM1 infection (Figure 4C). Next, we studied the
effects of re-expression of FOXM1 in differentiated P19
cells. P19 cell EBs were treated with RA for 4 days till the
Figure 2. Knockdown of Foxm1 resulted in spontaneous mesodermal differentiation of P19 cells. (A) Knockdown of Foxm1 increased the expres-
sion of differentiation marker Gata4 in P19 cells. P19 cells were infected with AdGFP or AdFoxm1siRNA (10pfu/cell) and gene expression analysis
of Foxm1 and Gata4 was performed by RT-PCR. (B) Knockdown of Foxm1 resulted in signiﬁcant decrease of SSEA-1 in P19 cells. Flow cytometry
was used to measure cell populations of SSEA-1 in P19 cells and AdFoxm1siRNA-infected P19 cells (3d). MEFs were used as negative control cells
and mouse ES cells were used as positive control cells. (C) Teratoma formation was abrogated in P19 cells with decreased levels of Foxm1.
Teratomas collected from the nude mice injected with Adcontrol or AdFoxm1siRNA-infected P19 cells are shown. (D) Teratomas formed with
AdFoxm1siRNA-infected P19 cells expressed mesodermal marker Brachyury and cardiac muscle-speciﬁc Actc1. The total RNAs isolated from
teratomas of P19 cells or AdFoxm1siRNA-infected P19 cells were analyzed for selected genes by RT-PCR. (E) Knockdown of Foxm1 in P19
cells resulted in differentiation of mesodermal derivatives in teratoma formation. Hematoxylin and eosin-stained sections from teratomas of
AdFoxm1siRNA-infected P19 cells after 3 weeks were shown.
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of Oct4, Nanog and Sox2. The differentiated cells were
infected with AdFOXM1 or control AdGFP and the ex-
pression analysis of selected genes were performed. We
found that the expression of exogenous FOXM1 in the
differentiated P19 cells (RA/EB 4day) started the expres-
sion of Oct4, Nanog, Sox2 and endogenous Foxm1
(Figure 4D). The analysis of Oct4 and Nanog protein
levels further conﬁrmed the results (Figure 4E). Flow
cytometry was performed to measure the SSEA-1 expres-
sion in the differentiated P19 cells infected with
AdFOXM1 or AdGFP. The differentiated P19 cells (RA
4d) were used as negative control cells. We found that the
AdFOXM1 infection in differentiated P19 cells resulted in
signiﬁcant increase of SSEA-1 (Figure 4F). The staining
of alkaline phosphatase was performed to show that
Figure 3. Foxm1 binds to and stimulates Oct4 promoter. (A) The predicted positions of putative Foxm1 binding sites in –5kb mouse Oct4 promoter
by gene sequence analysis and the positions of primers designed for ChIP assays. (B) FoxA1 bound to endogenous Oct4 promoter. ChIP assays were
used to show direct binding of Foxm1 to endogenous Oct4 promoter regions. The chromatin of P19 cells or RA-induced (3d) P19 cells was
cross-linked, sonicated, and immunoprecipitated (IP) with either Foxm1 antiserum or rabbit serum (control) and the amount of promoter DNA
associated with the IP chromatin was quantitated by RT–PCR with primers speciﬁc to different Oct4 promoter regions. The predicted size of the
PCR product was 170bp (ChIP1) or 187bp (ChIP2). (C) The –3-kb region of Oct4 promoter mediated the transcription activity of Foxm1. The Oct4
promoters with different length were constructed into luciferase reporter plasmid. The different reporter plasmid (1.5mg) and loading control
pRL-CMV luciferase reporter plasmid (20ng) were transfected into P19 cells with the CMV-FOXM1 expression vector (200ng) or a CMV
empty expression vector (200ng). Protein lysates were prepared at 24h following transfection, and used to measure dual Luciferase enzyme
activity. (D) The activities of Oct4 promoters with different length were inhibited at different degree during RA-induced P19 cell differentiation.
The different reporter plasmid (1.5mg) was transfected into P19 cells, followed by RA-induced differentiation. Three days later, the luciferase
activities were measured. (E) Only the Oct4 promoter that binds Foxm1 was inhibited by Foxm1 depletion. The different reporter plasmid
(1.5mg) was transfected into P19 cells, followed by AdFoxm1siRNA infection. Two days later, the luciferase activities were measured. (F) Point
mutations on Foxm1 binding sites of the –3kb Oct4 promoter inhibited Foxm1-mediated transcription activity. Intact or mutated –3kb Oct4
promoter-luciferase reporter plasmids (1.5mg) were transfected into P19 cells with the CMV-FOXM1 expression vector (200ng). The luciferase
activities were measured at 24h following transfection. The asterisks indicate statistically signiﬁcant changes: *P 0.05, **P 0.01, ***P 0.001.
Nucleic Acids Research, 2010,Vol.38, No. 22 8033FOXM1 overexpression also resulted in higher activities
of alkaline phosphatase in the differentiated P19 cells
infected with AdFOXM1 (Figure 4G). Therefore, these
data indicated a potential of Foxm1 to induce the expres-
sion of pluripotency-related genes in differentiated cells.
The overexpression of FOXM1 activated the expression of
pluripotency-related genes in human newborn ﬁbroblasts
We used human newborn ﬁbroblasts to test whether
overexpression of FOXM1 is able to induce the expression
of pluripotency-related genes in well differentiated somatic
cells. Human newborn ﬁbroblasts were infected three
times by AdFOXM1 (100pfu/cell) at 4 days interval
between each infection. Control AdLacZ infections
determined that almost 100% of the cells were infected
with the viral dosage at 100 pfu/cell (Supplementary
Figure S4). We noticed that the multiple AdFOXM1 in-
fections caused dramatic morphology changes of human
newborn ﬁbroblasts, which formed cell aggregates and
colonies afterwards (Figure 5A). Moreover, we found
that the colonies formed by AdFOXM1-infected human
newborn ﬁbroblasts possessed high levels of alkaline phos-
phatase activity (Figure 5B), suggesting that these colonies
started to have some characteristics similar to pluripotent
stem cells. Next, the human newborn ﬁbroblasts infected
with AdFOXM1 were analyzed for pluripotency markers
by RT-PCR. We found that the overexpression of
FOXM1 activated expression of OCT4, NANOG and
SOX2 in human newborn ﬁbroblasts (Figure 5C). Based
on the ﬁndings that mouse and human somatic cells can be
induced to acquire pluripotency by overexpression of
speciﬁc transcription factors such as OCT4 and
NANOG, the data of the ectopic expression of FOXM1
in human newborn ﬁbroblasts suggested that FOXM1
might be one of the candidates for reprogramming
differentiated somatic cells to iPS cells. Future work will
be focused on testing this possibility.
DISCUSSION
Pluripotent stem cells are unique in their ability to remain
self-renewing and pluripotency in vitro and these
processes are tightly regulated by a network of transcrip-
tion factors (41). Our results for the ﬁrst time deﬁne a role
for transcription factor Foxm1 in maintaining the
pluripotency of stem cells. The loss of Foxm1 expression
in pluripotent P19 cells results in the decreased activity of
alkaline phosphatase and the diminished expression of
Figure 4. Maintained expression of FOXM1 prevented the downregulation of pluripotency marker expression during P19 cell differentiation.
(A) Overexpression of FOXM1 in P19 cells by AdFOXM1 infection. P19 cells were infected with AdGFP or AdFOXM1 (10pfu/cell) and
mRNA levels of exogenous FOXM1, endogenous Foxm1, and loading control Cyclophilin were measured by RT-PCR. (B and C) P19 cells
infected with AdGFP or AdFOXM1 were induced to differentiation according to the standard protocol one day after viral infection. Gene expression
analysis of selected pluripotency genes was performed by RT–PCR (B) or western blotting (C). (D and E) The overexpression of FOXM1 activated
expression of Foxm1, Oct4, Nanog and Sox2 in the differentiated P19 cells. P19 cells were differentiated by RA treatment and 4 days later the cells
were infected with AdGFP or AdFOXM1. The expression analysis of selected genes was performed by RT-PCR (D) or western blotting (E). (F) The
overexpression of FOXM1 activated expression of of SSEA-1 in differentiated P19 cells. Flow cytometry was used to measure cell populations of
SSEA-1 in P19 cells (RA 4d), P19 cells (RA 4d)/AdGFP (3d), P19 cells (RA 4d)/AdFOXM1 (3d) and P19 cells. P19 cells (RA 4d) were used as
negative control cells and P19 cells were used as positive control cells. (G) P19 cells (RA 4d)/AdGFP (3d) and P19 cells (RA 4d)/AdFOXM1 (3d)
were stained for alkaline phosphatase.
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Foxm1 expression prevents the downregulation of Oct4
and Nanog during P19 cell differentiation. Furthermore,
we also found that the stable expression of FOXM1 in P19
cells prevented the downregulation of Oct4 expression
during RA-induced differentiation (Supplementary
Figure S5). Moreover, overexpression of FOXM1 alone
starts the expression of Oct4, Nanog and Sox2 in
RA-differentiated P19 cells or differentiated human
newborn ﬁbroblasts. It is well known that Oct4, Nanog
and Sox2 form a regulatory feedback circuit to maintain
pluripotency in human and mouse ESCs (42,43). This
regulatory circuit, in which all three transcription factors
regulate themselves as well as each other to form an inter-
connected autoregulation loop, has been identiﬁed to be
essential to the ESC identity. Our results conﬁrm that
Foxm1 maintains Oct4 expression by directly binding to
the Oct4 promoter, suggesting that Foxm1 is one of the
upstream regulators of Oct4 and possesses a plausible
position in the regulatory circuit of pluripotency.
This idea has been further conﬁrmed by the experiments
of the combinantion of Oct4 knockdown and FOXM1
overexpression in P19 cells. The Oct4 speciﬁc siRNA
transfection (10nM) that inhibits Oct4 expression
resulted in the decreased levels of the alkaline phosphatase
activity and the expression of Sox2 but not Nanog in
P19 cells (Supplementary Figure S6). The AdFOXM1
infection to the Oct4 knockdown cells caused the elevation
of alkaline phosphatase activity and the increased expres-
sion of Oct4 and Sox2 in these cells (Supplementary
Figure S6), implicating that the overexpression of
FOXM1 activates the transcription of Oct4 mRNAs
which may compensate the siRNA-induced Oct4 mRNA
degradation. Because Oct4 acts as a major regulator that
activates target genes encoding pluripotency/self-renewal
mechanisms and represses signaling pathways promoting
differentiation (42–45), it is reasonable to believe that
Foxm1 contributes to the hallmark characteristics of
pluripotent stem cells through its regulation on Oct4
expression.
Figure 5. The overexpression of FOXM1 activated the expression of pluripotency-related genes in human newborn ﬁbroblasts. (A) The morphology
of FOXM1-overexpressed human newborn ﬁbroblasts. Human newborn ﬁbroblasts were infected three times by AdFOXM1 (100pfu/cell) at 4 days
interval between each infection. Pictures of human newborn ﬁbroblasts or the cells post AdFOXM1 3X infections were taken at 200  magniﬁcation
using a TE2000 microscope (Nikon). (B) FOXM1-overexpressed human newborn ﬁbroblasts obtained high levels of alkaline phosphatase activity.
The human newborn ﬁbroblasts infected 3X with AdGFP or AdFOXM1 were stained for alkaline phosphatase. (C) The overexpression of FOXM1
activated expression of OCT4, NANOG and SOX2 in human newborn ﬁbroblasts. The human newborn ﬁbroblasts infected with AdFOXM1 were
analyzed for selected genes by RT-PCR (C). The human EC cell line NT2/D1 was used as a positive control of human pluripotent stem cells.
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of pathways that promote differentiation because
knockdown of Foxm1 results in activation of Gata4 ex-
pression and spontaneous differentiation of pluripotent
P19 cells to mesodermal derivatives such as cardiac
muscle especially. Although Gata4 is frequently used as
a marker for endodermal derivatives during differenti-
ation of pluripotent stem cells (46), Gata4 is also con-
sidered as a key regulator of cardiogenesis (39). Gata4
possesses the ability to specify endoderm with temporal
and spatial speciﬁcity and to facilitate the generation of
cardiomyocyte progenitors from associated mesoderm
(40). It is known that the overexpression of Gata4
enhances cardiogenesis in P19 cells (47). It has been
shown that a balance between levels of Nanog and
Gata4/Gata6 is necessary for differentiation into primitive
endoderm of the developing blastocyst (48). Nanog
represses the expression of Gata6 and Gata4, and
Gata4/Gata6 are upregulated in the absence of Nanog.
It is interesting to notice that knockdown of Foxm1 in
P19 cells results in the decreased expression of Nanog,
which may explain that knockdown of Foxm1 results in
activation of Gata4 expression in P19 cells. Whether the
increased expression of Gata4 is directly regulated by the
decrease of Foxm1 or through the reduced expression of
other pluripotency factors, such as Nanog, need to be
further investigated.
RA-initiated differentiation reduces the Foxm1 expres-
sion, which is correlated with the decreased expression of
many of the known pluripotency-related genes. The model
of RA-induced P19 cell differentiation, which mimics
events that occur during early development, has been
widely used for molecular analysis of in vitro differenti-
ation (49–54). As an important molecule for controlling
cell growth and differentiation in both embryo and adult,
RA functions by binding to the ligand-inducible transcrip-
tion factors (nuclear receptor proteins RARs and RXRs)
that activate or repress the transcription of downstream
target genes (55). RA-induced P19 cell differentiation is
followed by the repression of pluripotency genes such as
Oct4 (56). There are numerous publications suggesting
that the repression of pluripotency genes during differen-
tiation is regulated majorly by modiﬁcations of epigenet-
ics, such as DNA methylation of speciﬁc promoter regions
(57), histon modiﬁcations (58), and participation of
microRNAs (59). For example, differentiation-related
microRNA miR-124 is induced by RA to repress the ex-
pression of pluripotency-related Hes-1 during neuronal
differentiation of P19 cells (60). Given the evidence that
the reduction of Foxm1 expression is similar as that of
many pluripotency genes post RA treatment, we imagine
that the mechanisms of epigenetic modiﬁcation are
involved in the regulation of Foxm1 expression during
RA-induced P19 cell differentiation. This hypothesis will
be elucidated by future studies.
Direct reprogramming of somatic cells into induced
pluripotent stem cells (iPSCs) can be achieved by
overexpression of transcription factors (Oct4, Sox2,
c-Myc and Klf4 or Oct4, Sox2, Lin-28 and Nanog)
(12–14). In this study, we demonstrate that expressions
of Oct4, Nanog and Sox2 are upregulated by Foxm1 in
differentiated P19 cells or human newborn ﬁbroblasts. On
the other hand, Foxm1 has been shown to activate the
expression of c-Myc directly (61). Based on the ﬁndings
in this study and published evidences that the increase of
the cell division rate results in an accelerated kinetics
of iPSC formation (62) and Foxm1 is a major stimulator
of cell proliferation (27), we hypothesize that Foxm1 may
be one of the candidates to help reprogramming somatic
cells into iPSCs.
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